Intrathecal delivery could kickstart sales of Zolgensma, which have taken a while to get going but did rise 69% to $634 million in the first half of the year, setting it on course for blockbuster ...
The CHMP recommendation is another shot in the arm for Novartis’ gene therapy, coming shortly after it reported additional safety and efficacy data with intrathecal delivery of the gene therapy ...